Beam Therapeutics (BEAM) awards 31,750 RSUs to Chief Medical Officer Amy Simon

Rhea-AI Filing Summary

Simon Amy reported acquisition or exercise transactions in this Form 4 filing.

Beam Therapeutics Inc. granted Chief Medical Officer Amy Simon 31,750 restricted stock units (RSUs), each representing the right to receive one share of Beam common stock. The RSUs vest in four substantially equal annual installments on the first four anniversaries of the grant date, conditioned on her continued service. Following this award, she directly holds 109,114 shares of Beam common stock, reflecting a compensation-related equity grant rather than an open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simon Amy

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	31,750	$0.00	--

Holdings After Transaction: Common Stock — 109,114 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSUs Granted: 31,750 RSUs Post-transaction holdings: 109,114 shares Vesting schedule: 4 annual installments +1 more

4 metrics

RSUs Granted 31,750 RSUs Restricted stock units granted to CMO Amy Simon

Post-transaction holdings 109,114 shares Total Beam common stock beneficially owned after grant

Vesting schedule 4 annual installments RSUs vest over four substantially equal yearly tranches

Grant price $0.0000 per share Equity award at no cash cost to the reporting person

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, contingent right, vest

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan."

contingent right financial

"Each RSU represents the contingent right to receive one share of BEAM's common stock."

vest financial

"The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Amy

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		31,750(1)	A	$0.00	109,114	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon, Attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beam Therapeutics (BEAM) report for Amy Simon?

Beam Therapeutics reported that Chief Medical Officer Amy Simon received a grant of 31,750 restricted stock units. Each RSU represents one share of Beam common stock, awarded as equity compensation rather than through an open-market purchase or sale.

How many Beam Therapeutics (BEAM) shares does Amy Simon hold after this Form 4?

After the reported transaction, Amy Simon beneficially owns 109,114 shares of Beam common stock. This total includes the newly granted 31,750 restricted stock units, which will settle into shares as they vest over the four-year schedule.

How do the new RSUs for Amy Simon at Beam Therapeutics (BEAM) vest?

The 31,750 restricted stock units vest in four substantially equal installments on each of the first four anniversaries of the grant date. Vesting is contingent on Amy Simon’s continued service with Beam Therapeutics through each applicable vesting date.

Is Amy Simon’s Beam Therapeutics (BEAM) Form 4 a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not a market purchase. Amy Simon received 31,750 restricted stock units for no cash consideration, as part of Beam’s 2019 Equity Incentive Plan, rather than buying or selling shares on the open market.

What plan governed Amy Simon’s RSU grant at Beam Therapeutics (BEAM)?

The RSU grant to Amy Simon was made under the Beam Therapeutics Inc. 2019 Equity Incentive Plan. This plan allows the company to issue stock-based awards like restricted stock units to align executive compensation with long-term shareholder interests.